BCL2 and B-cell chronic lymphocytic leukemia: However, despite the clinical benefits demonstrated by these novel agents, a substantial fraction of patients eventually relapses owing to molecular mechanisms that confer resistance to targeted therapies, such as a point mutation in BCL2 recently identified in patients with CLL refractory to treatment with venetoclax (19), which calls for the development of new therapeutic strategies for selected patients with CLL.